JP2010507567A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507567A5
JP2010507567A5 JP2009523960A JP2009523960A JP2010507567A5 JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5 JP 2009523960 A JP2009523960 A JP 2009523960A JP 2009523960 A JP2009523960 A JP 2009523960A JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutically acceptable
cxcr4 inhibitor
acceptable salt
cxcr2 agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009523960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/075376 external-priority patent/WO2008019371A1/en
Publication of JP2010507567A publication Critical patent/JP2010507567A/ja
Publication of JP2010507567A5 publication Critical patent/JP2010507567A5/ja
Withdrawn legal-status Critical Current

Links

JP2009523960A 2006-08-07 2007-08-07 併用療法 Withdrawn JP2010507567A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83640906P 2006-08-07 2006-08-07
PCT/US2007/075376 WO2008019371A1 (en) 2006-08-07 2007-08-07 Combination therapy

Publications (2)

Publication Number Publication Date
JP2010507567A JP2010507567A (ja) 2010-03-11
JP2010507567A5 true JP2010507567A5 (cg-RX-API-DMAC7.html) 2010-09-30

Family

ID=39033325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523960A Withdrawn JP2010507567A (ja) 2006-08-07 2007-08-07 併用療法

Country Status (12)

Country Link
US (1) US20100178271A1 (cg-RX-API-DMAC7.html)
EP (1) EP2056853A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010507567A (cg-RX-API-DMAC7.html)
CN (1) CN101500595A (cg-RX-API-DMAC7.html)
AR (1) AR062271A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007281677A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0715393A2 (cg-RX-API-DMAC7.html)
CA (1) CA2659337A1 (cg-RX-API-DMAC7.html)
IL (1) IL196559A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009001445A (cg-RX-API-DMAC7.html)
RU (1) RU2009108289A (cg-RX-API-DMAC7.html)
WO (1) WO2008019371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2675032A1 (en) * 2007-01-09 2008-07-17 Cleveland Biolabs, Inc. Methods for increasing and mobilizing hematopoietic stem cells
US20110091486A1 (en) * 2008-02-29 2011-04-21 John Martin Brown Inhibition of post-radiation tumor growth
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
US20140219952A1 (en) 2010-03-23 2014-08-07 The Johns Hopkins University Methods of treatment using stem cell mobilizers
US8546353B2 (en) 2010-05-06 2013-10-01 Glykos Finland Oy Compounds and combinations
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
ES2370986B1 (es) * 2010-06-08 2012-11-16 Institut Quimic De Sarria Cets Nuevos inhibidores de cxcr4 como agentes anti-vih
WO2012047339A2 (en) 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012129073A2 (en) * 2011-03-18 2012-09-27 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
US9763980B2 (en) 2011-06-16 2017-09-19 Children's Medical Center Corporation Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US11116819B2 (en) * 2013-02-28 2021-09-14 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US12419619B2 (en) 2016-10-24 2025-09-23 Yale University Aspiration device
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
CA3080661A1 (en) 2017-11-03 2019-05-09 Roemer & Heigl Gmbh Extraction of stem cells from bone marrow niches
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
AU2018378804B2 (en) * 2017-12-06 2025-10-02 Ensoma, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022101359A1 (en) 2020-11-12 2022-05-19 Roemer & Heigl Gmbh Reversible release of stem cells from bone marrow niches
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
WO1994029341A1 (en) * 1993-06-08 1994-12-22 Smithkline Beecham Corporation Methods of enhancing bioactivity of chemokines
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
ATE428706T1 (de) * 1999-12-17 2009-05-15 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
HUP0302960A3 (en) * 2000-09-15 2007-03-28 Anormed Inc Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
CN1457339A (zh) * 2000-09-15 2003-11-19 阿诺麦德股份有限公司 趋化因子受体结合性杂环化合物
BR0114246A (pt) * 2000-09-29 2003-10-07 Anormed Inc Processo para preparação de poliaminas cìclicas contendo n nitrogênios de anel n-1 protegidas e seus produtos
US6853731B1 (en) * 2000-09-30 2005-02-08 Keen Personal Technologies, Inc. Digital video recorder employing a unique ID to interlock with encrypted video programs stored on a storage device
WO2002081727A2 (en) * 2001-04-03 2002-10-17 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
SI1411918T1 (sl) * 2001-07-31 2012-04-30 Genzyme Global S A R L Postopki za mobilizacijo progenitorskih/matičnih celic
WO2003048345A1 (en) * 2001-12-07 2003-06-12 Toolgen, Inc. Phenotypic screen of chimeric proteins
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7550484B2 (en) * 2003-04-22 2009-06-23 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7491735B2 (en) * 2003-12-11 2009-02-17 Genzyme Corporation Chemokine receptor binding compounds

Similar Documents

Publication Publication Date Title
JP2010507567A5 (cg-RX-API-DMAC7.html)
JP2009545620A5 (cg-RX-API-DMAC7.html)
RU2009108289A (ru) Комбинированная терапия
Pusic et al. Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells
RU2009107030A (ru) Комбинированная терапия
CA2560058A1 (en) A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP4353818A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
JP2007529532A5 (cg-RX-API-DMAC7.html)
MX2010010026A (es) Agente para tratar enfermedad.
JP2019503365A5 (cg-RX-API-DMAC7.html)
JP2010501159A5 (cg-RX-API-DMAC7.html)
JP2012067116A5 (cg-RX-API-DMAC7.html)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
JP2009545600A5 (cg-RX-API-DMAC7.html)
RS64074B1 (sr) Kombinacije imetelstata i venetoklaksa za lečenje akutne mijeloidne leukemije
CO6771406A2 (es) Una composición combinada
JP2013541583A5 (cg-RX-API-DMAC7.html)
JP2023012503A5 (cg-RX-API-DMAC7.html)
JP2009506054A5 (cg-RX-API-DMAC7.html)
WO2015126816A1 (en) Combination therapy for hematological malignancies
JP2020524179A5 (cg-RX-API-DMAC7.html)
JP2013540734A5 (cg-RX-API-DMAC7.html)
JP2017527551A5 (cg-RX-API-DMAC7.html)